Research programme: LPM Leuprorelin - Soligenix

Drug Profile

Research programme: LPM Leuprorelin - Soligenix

Alternative Names: LPM™ Leuprolide

Latest Information Update: 05 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DOR BioPharma
  • Developer Soligenix
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone inhibitors; Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Endometriosis; Prostate cancer

Most Recent Events

  • 05 Jul 2013 No development reported - Preclinical for Endometriosis in USA (PO)
  • 05 Jul 2013 No development reported - Preclinical for Prostate cancer in USA (PO)
  • 19 May 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top